High-grade B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for High-grade B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]
Phase 1 trial results of NT-I7 after CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma show early efficacy signal…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating anakinra to prevent severe CAR-T cell-related encephalopathy in patients with recurrent or refractory diffuse large…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma [Phase 1]
A Phase 1 exploratory study evaluated CD19-targeted CAR T cells (BZ019) in relapsed/refractory B-cell lymphomas, including diffuse large B-c…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Compassionate Use (CU) Program of Odronextamab
Compassionate-use program update for odronextamab in relapsed or refractory B-cell lymphomas, including follicular lymphoma and diffuse larg…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of acalabrutinib with anti-CD19 CAR T-cell therapy for various B-cell lymphomas, in…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 clinical trial assessing the combination of loncastuximab tesirine and epcoritamab in relapsed/refractory aggressive B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma [Phase 2]
A Phase 2 clinical trial update notes Polatuzumab Vedotin in combination chemotherapy for previously untreated diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]
Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 study evaluating anakinra to reduce CAR-T–related toxicity in patients with relapsed or refractory diffuse large B-cell lymphoma has…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update indicates Sepantronium bromide is being studied for high-grade B-cell lymphomas, with the study currently ac…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A multicentre, open-label Phase 1/2 trial is evaluating frontline regimens R-CHOP/Pola-RCHP and Glofitamab in younger patients with high-ris…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL [Phase 1]
Phase 1 trial results for FT596 CAR-T cells with Rituximab as relapse prevention after autologous HSCT in non-Hodgkin lymphoma were posted, …
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas [Phase 1]
Phase 1 trial evaluating copanlisib with dose-adjusted EPOCH-R in relapsed and refractory Burkitt lymphoma and other high-grade B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL [Phase 2]
Phase 2 trial evaluating DA-EPOCH-R induction followed by nivolumab consolidation in newly diagnosed high-grade B-cell lymphoma with MYC, BC…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating mogamulizumab in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma and rela…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Treatment for Advanced B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial completed for treatment of advanced B-cell lymphoma, including diffuse large B-cell lymphoma and Burkitt's lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update investigating toripalimab in combination with rituximab followed by R-CHOP for elderly patients with untreated diffuse…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma [Phase 2]
Phase 2 protocol update for DLCL002 in high-risk aggressive B-cell lymphoma patients.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 trial evaluating axicabtagene ciloleucel (KTE-C19) for adults with refractory or relapse…
-
CLINICAL_TRIALS trial_result · 2021-09-20Clinical Trial Update: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL [Phase 2]
Phase II trial update examining tirelizumab with the R2-ICE regimen for relapsed/refractory diffuse large B-cell lymphoma and high-grade B-c…